Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm.
Aged
Aged, 80 and over
Aortic Aneurysm, Abdominal
/ epidemiology
Aortic Rupture
/ epidemiology
Australia
/ epidemiology
Cohort Studies
Cost-Benefit Analysis
Diabetes Mellitus
/ drug therapy
Drug Prescriptions
Endovascular Procedures
/ methods
Female
Humans
Incidence
Kaplan-Meier Estimate
Male
Metformin
/ administration & dosage
Prospective Studies
Risk Factors
Abdominal aortic aneurysm
Metformin
Surgical repair
Journal
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
11
04
2018
accepted:
30
07
2018
pubmed:
4
9
2018
medline:
18
6
2019
entrez:
4
9
2018
Statut:
ppublish
Résumé
Currently there is no drug therapy for abdominal aortic aneurysm (AAA) and most previous investigations have focused on imaging rather than clinical outcomes. The aim of this study was to assess whether AAA related clinical events were lower in patients prescribed metformin. This was a prospective cohort observational study performed in three cities in Australia, which was designed to study risk factors for clinical events not simply to focus on metformin. Patients with an asymptomatic unrepaired AAA of any diameter ≥30 mm were recruited from hospital outpatient clinics and surveillance programs run at four centres. The main outcome was the requirement for AAA repair or AAA related mortality (AAA events). The association between metformin prescription and AAA events was assessed using Kaplan-Meier analysis and Cox proportional hazard analysis. Patients (1,080) with a mean (SD) initial AAA diameter of 46.1 (11.3) mm were followed for a mean (SD) of 2.5 (3.1) years until an AAA event (n = 454), death (n = 176), loss to follow up (n = 128), or completion of current follow up (n = 322). Patients with diabetes who were prescribed metformin (adjusted HR 0.63, 95% CI 0.44-0.93), but not patients with diabetes who were not prescribed metformin (adjusted HR 1.15, 95% CI 0.83-1.59), had a lower incidence of AAA events compared with those without diabetes. Findings were similar in sensitivity analyses restricted to patients with an initial AAA diameter ≤50 mm and patients with a minimum follow up of six months before an AAA event. These findings suggest that clinically important AAA events may be reduced in patients with diabetes who are prescribed metformin, but not those with diabetes receiving other treatments. A randomised controlled trial is needed to definitively test whether metformin reduces AAA related clinical events in patients with small AAAs who do not have diabetes.
Identifiants
pubmed: 30174271
pii: S1078-5884(18)30509-4
doi: 10.1016/j.ejvs.2018.07.035
pii:
doi:
Substances chimiques
Metformin
9100L32L2N
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-101Informations de copyright
Crown Copyright © 2018. Published by Elsevier B.V. All rights reserved.